Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 12, Issue 3, 2012, Pages 343-352

  Lejbkowicz, Izabella ^a   Caspi, Opher ^b   Miller, Ariel ^a,c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c CARMEL MEDICAL CENTER   (Israel)

Author keywords

adherence; empowerment; health literacy; multiple sclerosis; participatory; patient centered; patient reported outcomes; personalized medicine; pharmacogenetics; predictive; telemedicine

Indexed keywords

CLINICAL PRACTICE; EMPOWERMENT; FOLLOW UP; HEALTH CARE; HEALTH CARE PERSONNEL; HEALTH LITERACY; HUMAN; MEDICAL DECISION MAKING; MEDICINE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHYSICIAN ATTITUDE; PREVENTIVE MEDICINE; REVIEW; TELEMEDICINE; BEHAVIOR; METHODOLOGY; PSYCHOLOGICAL ASPECT;

HUMANS; INDIVIDUALIZED MEDICINE; MULTIPLE SCLEROSIS; PATIENT PARTICIPATION; POWER (PSYCHOLOGY);

EID: 84857927145     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.161     Document Type: Review

References (82)

1. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J. Proteome Res. 3(2), 179-196 (2004). (Pubitemid 38500984)
2. Auffray C, Charron D, Hood L. Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med. 2(8), 57 (2010).
3. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat. Rev. Clin. Oncol. 8(3), 184-187 (2011).
4. Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele e 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43(8), 1467-1472 (1993). (Pubitemid 23230526)
5. Piccart-Gebhart MJ, Procter M, Leyland- Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005). (Pubitemid 41464705)
6. Chen P, Lin JJ, Lu CS et al. Carbamazepine-induced toxic effects and HLA-B. 1502 screening in Taiwan. N. Engl. J. Med. 364(12), 1126-1133 (2011).
7. McCormack M, Alfirevic A, Bourgeois S et al. HLA-A. 3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364(12), 1134-1143 (2011).
8. Lejbkowicz I, Paperna T, Stein N, Dishon S, Miller A. Internet usage by patients with multiple sclerosis: implications to participatory medicine and personalized healthcare. Mult. Scler. Int. 2010, 640749 (2010) .
9. Finkelstein J, Lapshin O, Castro H, Cha E, Provance PG. Home-based physical telerehabilitation in patients with multiple sclerosis: a pilot study. J. Rehabil. Res. Dev. 45(9), 1361-1373 (2008).
10. Zissman K, Lejbkowicz I, Miller A. Telemedicine for multiple sclerosis patients: assessment using Health Value Compass. Mult. Scler. doi:10.1177/1352458511421918 (2011) (Epub ahead of print).
11. Shatil E, Metzer A, Horvitz O, Miller A. Home-based personalized cognitive training in MS patients: a study of adherence and cognitive performance. NeuroRehabilitation 26(2), 143-153 (2010).
12. Nicholson JK, Wilson ID, Lindon JC. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12(1), 103-111 (2011).
13. Simopoulos AP. Nutrigenetics/ nutrigenomics. Annu. Rev. Public Health 31, 53-68 (2010).
14. Broekhuizen K, van Poppel MN, Koppes LL, Brug J, van Mechelen W. A tailored lifestyle intervention to reduce the cardiovascular disease risk of individuals with familial hypercholesterolemia (FH): design of the PRO-FIT randomised controlled trial. BMC Public Health 10, 69 (2010).
15. Frosch DL, Kaplan RM. Shared decision making in clinical medicine: past research and future directions. Am. J. Prev. Med. 17(4), 285-294 (1999). (Pubitemid 29505475)
16. Greenfield S, Kaplan S, Ware JE Jr. Expanding patient involvement in care. Effects on patient outcomes. Ann. Intern. Med. 102(4), 520-528 (1985). (Pubitemid 15109013)
17. Miller A, Avidan N, Tzunz-Henig N et al. Translation towards personalized medicine in multiple sclerosis. J. Neurol. Sci. 274(1-2), 68-75 (2008).
18. Grossman I, Avidan N, Singer C et al. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet. Genomics 17(8), 657-666 (2007). (Pubitemid 47057715)
19. Vandenbroeck K, Urcelay E, Comabella M. IFN-b pharmacogenomics in multiple sclerosis. Pharmacogenomics 11(8), 1137-1148 (2010).
20. Miller A, Paperna T, Caspi O, Lejbkowicz I, Staun-Ram E, Avidan N. Theranostics and translation towards personalized medicine for multiple sclerosis. In:Personalized Medicine, Healthcare and Integrative NeuroScience. Gordon E, Koslow SH (Eds). Oxford University Press, Oxford, UK, 205-254 (2010).
21. Ozdemir V, Husereau D, Hyland S, Samper S, Salleh MZ. Personalized medicine beyond genomics: new technologies, global health diplomacy and anticipatory governance. Curr. Pharmacogenomics Person. Med. 7(4), 225-230 (2009).
22. Chiovetti A. Bridging the gap between health literacy and patient education for people with multiple sclerosis. J. Neurosci. Nurs. 38(5), 374-378 (2006).
23. Depold Hohler A, Doyle Lee J, Schulman EA, Schafer JA, Flippen C. Invited article: improving safety for the neurologic patient: evaluating medications, literacy, and abuse. Neurology 75(8), 742-746 (2010).
24. Wollin J, Dale H, Spense N, Walsh A. What people with newly diagnosed MS (and their families and friends) need to know. Int. J. MS Care 2(3), 29-38 (2000).
25. Harland J, Bath P. Assessing the quality of websites providing information on multiple sclerosis: evaluating tools and comparing sites. Health Informatics J. 13(3), 207-221 (2007). (Pubitemid 47308349)
26. Atreja A, Mehta N, Miller D et al. One size does not fit all: using qualitative methods to inform the development of an internet portal for multiple sclerosis patients. AMIA Annu. Symp. Proc. 2005, 16-20 (2005).
27. Hay MC, Cadigan RJ, Khanna D et al. Prepared patients: internet information seeking by new rheumatology patients. Arthritis Rheum. 59(4), 575-582 (2008). (Pubitemid 351563542)
28. Ball MJ, Lillis J. E-health: transforming the physician/patient relationship. Int. J. Med. Inform. 61(1), 1-10 (2001). (Pubitemid 32193020)
29. Potts HW, Wyatt JC. Survey of doctors' experience of patients using the internet. J. Med. Internet Res. 4(1), e5 (2002).
30. Wardell L, Stanley H, Laizner A, Lapierre Y. Multiple sclerosis patients' interest in and likelihood of using online health-care services. Int. J. MS Care 11, 79-89 (2009).
31. Twomey F, Robinson K. Pilot study of participating in a fatigue management programme for clients with multiple sclerosis. Disabil. Rehabil. 32(10), 791-800 (2010).
32. Motl RW, McAuley E. Pathways between physical activity and quality of life in adults with multiple sclerosis. Health Psychol. 28(6), 682-689 (2009).
33. Snook EM, Motl RW. Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabil. Neural Repair 23(2), 108-116 (2009).
34. Motl RW, Gosney JL. Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis. Mult. Scler. 14(1), 129-135 (2008). (Pubitemid 351541406)
35. Motl RW, Dlugonski D, Wojcicki TR, McAuley E, Mohr DC. Internet intervention for increasing physical activity in persons with multiple sclerosis. Mult. Scler. 17(1), 116-128 (2011).
36. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv. Ther. 28(1), 51-61 (2011).
37. Bruce JM, Hancock LM, Lynch SG. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Mult. Scler. 16(1), 112-120 (2010).
38. Devonshire V, Lapierre Y, Macdonell R et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing- remitting multiple sclerosis. Eur. J. Neurol. 18(1), 69-77 (2011).
39. Bruce JM, Hancock LM, Arnett P, Lynch S. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J. Behav. Med. 33(3), 219-227 (2010).
40. Saunders C, Caon C, Smrtka J, Shoemaker J. Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis. J. Neurosci. Nurs. 42(5 Suppl.), S10-S18 (2010).
41. Treadaway K, Cutter G, Salter A et al. Factors that influence adherence with disease-modifying therapy in MS. J. Neurol. 256(4), 568-576 (2009).
42. Yamout BI, Dahdaleh M, Al Jumah MA et al. Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory Group. Int. J. Neurosci. 120(4), 273-279 (2010).
43. Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J. Neurol. 255(Suppl. 6), 87-92 (2008).
44. Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin. Drug Deliv. 6(9), 995-1002 (2009).
45. Bruce JM, Lynch SG. Multiple sclerosis: MS treatment adherence - how to keep patients on medication? Nat. Rev. Neurol. 7(8), 421-422 (2011).
46. Turner AP, Kivlahan DR, Sloan AP, Haselkorn JK. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the Health Beliefs Model. Mult. Scler. 13(9), 1146-1152 (2007). (Pubitemid 351541418)
47. Miller W, Rollnick S. Motivational Interviewing: Preparing People to Change. Guilford Press, NY, USA (2002).
48. Berger BA, Liang H, Hudmon KS. Evaluation of software-based telephone counseling to enhance medication persistency among patients with multiple sclerosis. J. Am. Pharm. Assoc. (2003) 45(4), 466-472 (2005). (Pubitemid 46037287)
49. Prochaska J, DiClemente C. The Transtheoretical Approach: Crossing the Traditional Boundaries of Therapy. Krieger Publishing Company, Melbourne, FL, USA (1984).
50. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11), 1444-1452 (1983). (Pubitemid 14237132)
51. Goldman MD, Motl RW, Rudick RA. Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther. Adv. Neurol. Disord. 3(4), 229-239 (2010).
52. Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. MRI as an outcome in multiple sclerosis clinical trials. Neurology 72(8), 705-711 (2009).
53. Riazi A. Patient-reported outcome measures in multiple sclerosis. Int. MS J. 13(3), 92-99 (2006). (Pubitemid 44898370)
54. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 60(1), 31-36 (2003). (Pubitemid 36070640)
55. Motl RW, McAuley E, Mullen S. Longitudinal measurement invariance of the Multiple Sclerosis Walking Scale-12. J. Neurol. Sci. 305(1-2), 75-79 (2011).
56. Motl RW, Snook EM. Confirmation and extension of the validity of the Multiple Sclerosis Walking Scale-12 (MSWS-12). J. Neurol. Sci. 268(1-2), 69-73 (2008). (Pubitemid 351389469)
57. Goodman AD, Brown TR, Edwards KR et al. A Phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann. Neurol. 68(4), 494-502 (2010).
58. Goodman AD, Brown TR, Krupp LB et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373(9665), 732-738 (2009).
59. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult. Scler. 5(5), 349-354 (1999). (Pubitemid 29505050)
60. Hadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain 127(1-2), 35-41 (2007). (Pubitemid 44959422)
61. Motl RW, Dlugonski D, Suh Y, Weikert M, Fernhall B, Goldman M. Accelerometry and its association with objective markers of walking limitations in ambulatory adults with multiple sclerosis. Arch. Phys. Med. Rehabil. 91(12), 1942-1947 (2010).
62. Wicks P, Massagli M, Kulkarni A, Dastani H. Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ). J. Med. Internet Res. 13(1), e12 (2011).
63. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 46(10), 1121-1123 (1989). (Pubitemid 19246303)
64. Mills R, Young C, Nicholas R, Pallant J, Tennant A. Rasch analysis of the Fatigue Severity Scale in multiple sclerosis. Mult. Scler. 15(1), 81-87 (2009).
65. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual. Life Res. 4(3), 187-206 (1995).
66. Cella DF, Dineen K, Arnason B et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 47(1), 129-139 (1996). (Pubitemid 26243873)
67. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult. Scler. 5(4), 251-259 (1999). (Pubitemid 29405621)
68. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 124(Pt 5), 962-973 (2001). (Pubitemid 32458508)
69. Ford HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson MH. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin. Rehabil. 15(3), 247-258 (2001). (Pubitemid 32475720)
70. Benedict RH, Wahlig E, Bakshi R et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J. Neurol. Sci. 231(1-2), 29-34 (2005). (Pubitemid 40432023)
71. Mitchell AJ, Benito-Leon J, Gonzalez JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 4(9), 556-566 (2005). (Pubitemid 41139977)
72. Opara JA, Jaracz K, Brola W. Quality of life in multiple sclerosis. J. Med. Life 3(4), 352-358 (2010).
73. Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference. Science 324(5933), 1394-1395 (2009).
74. Fisher RS. Tracking epilepsy with an electronic diary. Acta Paediatr. 99(4), 516-518 (2010).
75. Chafe R, Born KB, Slutsky AS, Laupacis A. The rise of people power. Nature 472(7344), 410-411 (2011).
76. Zamboni P, Galeotti R, Menegatti E et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 80(4), 392-399 (2009).
77. Baracchini C, Perini P, Calabrese M, Causin F, Rinaldi F, Gallo P. No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Ann. Neurol. 69(1), 90-99 (2011).
78. Mayer CA, Pfeilschifter W, Lorenz MW et al. The perfect crime? CCSVI not leaving a trace in MS. J. Neurol. Neurosurg. Psychiatry 82(4), 436-440 (2011).
79. Frueh FW, Greely HT, Green RC, Hogarth S, Siegel S. The future of direct-to-consumer clinical genetic tests. Nat. Rev. Genet. 12(7), 511-515 (2011).
80. Basch E. The missing voice of patients in drug-safety reporting. N. Engl. J. Med. 362(10), 865-869 (2010).
81. Sadee W. Genomics and personalized medicine. Int. J. Pharm. 415(1-2), 2-4 (2011).
82. Wilke RA, Xu H, Denny JC et al. The emerging role of electronic medical records in pharmacogenomics. Clin. Pharmacol. Ther. 89(3), 379-386 (2011).